|
GGCX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.36130000050194E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.35630000003473E-06 |
| Normal-vs-Stage2 |
1.300090E-02 |
| Normal-vs-Stage3 |
2.38819997111506E-09 |
| Normal-vs-Stage4 |
3.36489947017071E-10 |
| Stage1-vs-Stage2 |
4.869800E-01 |
| Stage1-vs-Stage3 |
5.881700E-02 |
| Stage1-vs-Stage4 |
3.616500E-03 |
| Stage2-vs-Stage3 |
8.552400E-02 |
| Stage2-vs-Stage4 |
2.306400E-02 |
| Stage3-vs-Stage4 |
3.647600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93860000052837E-07 |
| Normal-vs-AfricanAmerican |
1.732190E-01 |
| Normal-vs-Asian |
4.794800E-04 |
| Caucasian-vs-AfricanAmerican |
7.389700E-02 |
| Caucasian-vs-Asian |
6.307000E-01 |
| AfricanAmerican-vs-Asian |
2.582000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.65479999995E-08 |
| Normal-vs-Female |
8.73570000003987E-07 |
| Male-vs-Female |
1.070640E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.07429999998787E-06 |
| Normal-vs-Age(41-60Yrs) |
1.5219099999908E-05 |
| Normal-vs-Age(61-80Yrs) |
5.19099999651829E-08 |
| Normal-vs-Age(81-100Yrs) |
6.822000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.445600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.997830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.078400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.871950E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.238000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.867400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.57680000001381E-06 |
| Classical-VS-Follicular |
4.757500E-04 |
| Classical-VS-Other |
8.739600E-02 |
| Classical-VS-Normal |
9.80000000000425E-05 |
| Tall-VS-Follicular |
2.852600E-01 |
| Tall-VS-Other |
9.381000E-01 |
| Tall-VS-Normal |
3.86970455679148E-11 |
| Follicular-VS-Other |
6.301000E-01 |
| Follicular-VS-Normal |
2.06989999584906E-08 |
| Other-VS-Normal |
8.438100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.20309999973989E-07 |
| Normal-vs-N1 |
7.63749996579577E-09 |
| N0-vs-N1 |
3.620500E-02 |
|
|
